Showing papers by "Ursula F. Bailer published in 2003"
TL;DR: Most of the neuroendocrine and neuropeptide alterations apparent during symptomatic episodes of AN and BN tend to normalize after recovery, suggesting that most of the disturbances are consequences rather than causes of malnutrition, weight loss and/or altered meal patterns.
Abstract: Neuropeptides play an important role in the regulation of feeding behavior and obesity. The mechanisms for controlling food intake involve a complicated interplay between peripheral systems (including gustatory stimulation, gastrointestinal peptide secretion, and vagal afferent nerve responses) and central nervous system (CNS) neuropeptides and/or monoamines. These neuronal systems include neuropeptides (CRH, opioids, neuropeptide-Y (NPY) and peptide YY (PYY), vasopressin and oxytocin, CCK, and leptin) and monamines (serotonin, dopamine, norepinephrine). In addition to regulating eating behavior, a number of CNS neuropeptides participate in the regulation of neuroendocrine pathways. Thus, clinical studies have evaluated the possibility that CNS neuropeptide alterations may contribute to dysregulated secretion of the gonadal hormones, cortisol, thyroid hormones and growth hormone in the eating disorders. Most of the neuroendocrine and neuropeptide alterations apparent during symptomatic episodes of AN and BN tend to normalize after recovery. This observation suggests that most of the disturbances are consequences rather than causes of malnutrition, weight loss and/or altered meal patterns. Still, an understanding of these neuropeptide disturbances may shed light on why many people with AN or BN cannot easily "reverse" their illness and even after weight gain and normalized eating patterns, many individuals who have recovered from AN or BN have physiological, behavioral and psychological symptoms that persist for extended periods of time.
106 citations
TL;DR: The preliminary data give rise to the notion that milnacipran may be promising in the treatment of bulimia nervosa, and there was a concomitant decrease of depression ratings (HAMD, BDI).
33 citations
01 Jan 2003
TL;DR: Die Kombination von Psychothera-pie und Psychopharmakotherapie ist wahrscheinlich meist eine sehr wir-kungsvolle Behandlung der Depression.
Abstract: Die Kombination von Psychothera-pie und Psychopharmakotherapie ist wahrscheinlich meist eine sehr wir-kungsvolle Behandlung der Depression , auch bei Anwendung der sehr niederschwelligen Bibliotherapie.
4 citations
01 Jan 2003
TL;DR: The preliminary data give rise to the notion that milnacipran may be promising in the treatment of bulimia nervosa, and there was a concomitant decrease of depression ratings (HAMD, BDI).
Abstract: Controlled trials in patients with bulimia nervosa have demonstrated efficacy of antidepressant medications with serotonergic function (e.g. fluoxetine) as well as noradrenergic function (e.g. desipramine). Sixteen out-patients with bulimia nervosa according to DSM-IV criteria were treated in a drug surveillance with 100 mg of milnacipran, a specific serotonin and noradrenaline reuptake inhibitor (SNRI). Ten patients completed the 8-week observation period. The reasons for premature attrition were improvement in one patient (no. 12), a generalized exanthema in one patient (no. 7), severe nausea in one patient (no. 8) and non-compliance due to non-drug-related reasons in three patients (no. 1, 2, and 16). An intent-to-treat analysis exhibited a significant reduction in weekly binge eating and vomiting frequency from baseline to the end of treatment. Three patients stopped binge eating and purging completely during the last week of treatment. Furthermore, there was a concomitant decrease of depression ratings (HAMD, BDI). Our preliminary data give rise to the notion that milnacipran may be promising in the treatment of bulimia nervosa. 2002 Elsevier Science B.V./ECNP All rights reserved.